SCHEMBL6035227

SCHEMBL6035227

Cc1n[nH]cc1C(Oc1ccc(CC(=O)O)cc1)c1ccccn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
TSHR P16473 2/20 0.36
PPARD Q03181 2/20 0.36
SRD5A2 P31213 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ABCB11 O95342 1/20 0.36
ESR1 P03372 1/20 0.36
CYP3A4 P08684 1/20 0.36
ADRA2A P08913 1/20 0.36
CYP2C9 P11712 1/20 0.36
PDE4A P27815 1/20 0.36
ADRA1A P35348 1/20 0.36
OPRK1 P41145 1/20 0.36
STAT6 P42226 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HIF1A Q16665 1/20 0.36
GPR55 Q9Y2T6 1/20 0.36
ALDH1A1 P00352 2/20 0.35
CYP4F2 P78329 2/20 0.35
CYP4A11 Q02928 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034579 0.90 FFAR1 (0.46) LMNA
SCHEMBL5380398 0.87 PPARG (0.34) LMNATSHRKDM4EABCB11ESR1
SCHEMBL4033999 0.80 KDM4E (0.40) LMNATSHRKDM4EABCB11ESR1
SCHEMBL5376445 0.78 PPARG (0.34) LMNAPPARDCYP2C9GAAPTGDR2
SCHEMBL6035085 0.71 PPARD (0.45) LMNAPPARDPTGDR2
SCHEMBL4036792 0.70 MAPT (0.52) LMNATSHRKDM4EABCB11ESR1
SCHEMBL25033296 0.68 SRD5A2 (0.57) LMNATSHRSRD5A2GAA
SCHEMBL4890891 0.67 SLC6A3 (0.61) LMNATSHRKDM4EABCB11ESR1
SCHEMBL14675707 0.64 SRD5A2 (0.49) PPARDSRD5A2ALDH1A1MEN1GAA
Hydrochloric Acid SCHEMBL9567430 0.64 ALDH1A1 (0.45) LMNATSHRKDM4EABCB11ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed
EP-1513817-A1 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY Takeda Pharmaceutical Company Limited (JP) 2005-03-16 EP disclosed
WO-2003099793-A9 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL (JP) 2005-02-10 WO disclosed
WO-2003099793-A1 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2003-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 LMNA 1816/4885TSHR 910/4885PPARD 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.